Background: Repeated administration of amphetamine elicits a progressive enhancement in behavioral and subjective responses to the drug and an increase in amphetamine-induced dopamine release. This enhancement is called sensitization and is able to induce changes in the response of the brain dopamine system to amphetamines mimicking certain aspects of dopaminergic dysfunction in schizophrenia. Objectives: We are conducting experiments using positron emission tomography (PET) and the D 2/3 receptor agonist radioligand [
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Background: Repeated administration of amphetamine elicits a progressive enhancement in behavioral and subjective responses to the drug and an increase in amphetamine-induced dopamine release. This enhancement is called sensitization and is able to induce changes in the response of the brain dopamine system to amphetamines mimicking certain aspects of dopaminergic dysfunction in schizophrenia. Objectives: We are conducting experiments using positron emission tomography (PET) and the D 2/3 receptor agonist radioligand [
11 C]-(+)-PHNO, which is currently the optimal method for studying fluctuations in extracellular dopamine in the living human brain. Our primary objective is to compare the amphetamine-sensitized state in healthy controls to the amphetamine-response in schizophrenia on a neurochemical and behavioral level. Amphetamine-induced dopamine release is partly controlled by inhibitory action of D 3 receptors. Studies using D 3 -selective compounds have shown that a large proportion of 
OBJECTIVES:
To explore hospitalization, drug utilization and clinical outcomes from medical records of newly diagnosed schizophrenia patients during first 12 months of treatment with once-monthly paliperidone palmitate (PP). Methods: International, multicenter, retrospective, observational study. Outcomes presented: baseline (BL) characteristics and demographics, clinically relevant improvements in disease severity (ie ≥20% decrease in PANSS or BPRS total score or CGI-S Change≥-2 or CGI-C≥3, with no score showing worsening) and clinically relevant functional improvement (ie change in PSP total score≥+7 points or change in GAF total score≥+20 points, with no score showing worsening) from BL to last-observationcarried-forward endpoint (LOCF-EP) within 12-month documentation period, mean mode PP dose and adverse drug reactions. Results: 84 patients analyzed: 69% male, mean age at initiation of PP was 24.1(SD2.7) years, Mean BL weight was 78.7(SD16.0)kg and 80.0(SD14.7)kg at LOCF-EP, with a mean change of 1.2(SD3.9) kg; mean time from first psychotic episode to initiation of PP was 5.5(SD3.3) months. At LOCF-EP 86.6% achieved a clinically relevant improvement (71/84, Kaplan-Meier median time from initiation of PP: 52.4 days). 63.4% achieved a clinically relevant functional improvement (52/84, Kaplan-Meier median time from initiation of PP: 53.1 days). PP mean mode maintenance dose was 96.4(SD19.8) mg. ADRs reported in ≥5% of patients were weight increase 9.1% and hyperprolactinemia 5.7%. Conclusions: Treatment with once-monthly PP was well tolerated and associated with clinically relevant improvements in disease severity and functioning in young, newly diagnosed schizophrenia patients.
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